![]() ![]() A health systems perspective applying health policy and system research frameworks (HPSR) is hence needed in the generation of evidence on access to essential medicines. Second, even where published research on medicines is available in LMICs the evidence has usually not been well integrated the within wider health systems responses and the pharmaceutical and health systems stakeholders continue to function in silos. First, although reasonably sufficient information from the Organization for Economic Co-operation and Development (OECD) countries is available on essential medicine access, the data from LMICs is often weak, fragmented and requires collation. There are a number of gaps related to evidence on access to essential medicines. Cohesive evidence is essential to understanding, planning, monitoring and evaluating access to medicines. However access to essential medicines in low and middle income countries (LMICs) remains questionable. Support for access to essential medicines is pledged under Millennium Development Goal 8 and the provision of affordable, high quality and appropriate essential medicines is a component of functioning health systems. Active moderate to severe HS in adolescents from 12 yr w/ inadequate response to conventional systemic HS therapy.Essential medicines, as defined by World Health Organization (WHO), are those that satisfy the health care needs of majority of the population. Chronic non-infectious anterior uveitis in patients from 2 yr w/ inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. Severe chronic plaque psoriasis in childn & adolescents from 4 yr w/ inadequate response to or are inappropriate candidates for topical- & phototherapy. Moderate to severe active Crohn's disease in ped patients 6-17 yr w/ inadequate response to conventional therapy eg, primary nutrition therapy, corticosteroids &/or immunomodulator, or who are intolerant to or have CI for such therapies. Active enthesitis-related arthritis in patients ≥6 yr w/ inadequate response to or who are intolerant of conventional therapy. Ped: Monotherapy or in combination w/ MTX for active polyarticular juvenile idiopathic arthritis (pJIA) in patients >2 yr w/ inadequate response to ≥1 DMARDs. Non-infectious intermediate, posterior & panuveitis in patients w/ inadequate response to corticosteroids, in need of corticosteroid-sparing or in whom corticosteroids is inappropriate. ![]() Active moderate to severe hidradenitis suppurativa (HS) in patients w/ inadequate response to conventional systemic HS therapy. ![]() Moderate to severe active ulcerative colitis in patients w/ inadequate response to conventional therapy including corticosteroids &/or 6-mercaptopurine or azathioprine, or who are intolerant to, or have medical CI for such therapies. Moderate to severe active Crohn's disease in patients w/ inadequate response to conventional therapy, or who have lost response to or are infliximab-intolerant. Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic- or phototherapy & when other systemic therapies are medically less appropriate. Non-radiographic axial spondyloarthritis (nr-axSpA) in patients w/ inadequate response to or are intolerant to NSAIDs. Monotherapy or in combination w/ DMARDs in patients w/ active psoriatic arthritis. Indications/Uses : Adult: Monotherapy or in combination w/ MTX or other DMARDs in patients w/ moderate to severe active RA. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |